Helus Pharma prices $50M share offering at $4.85 per share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
Helus Pharma™ Announces US$50 Million Underwritten Offering
June 24, 2026 6:01 AM EDTNEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the Company or Helus Pharma), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (NSAs), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the Common Shares) at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the Offering).
... More